Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai, Inc. and Exelixis, Inc.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO GI: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular Carcinoma

ASCO GI: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular Carcinoma


January 17, 2019
7:00PM-9:00PM
Dinner and registration: 6:30 PM – 7:00 PM

InterContinental San Francisco
Meeting Room: InterContinental Ballroom A & B
888 Howard Street
San Francisco, CA 94103

Overview:

Progress in the management of hepatocellular carcinoma (HCC) has exploded in recent years, with robust clinical investigation leading to breakthroughs in therapy. Although, historically, HCC has been associated with poor outcomes, the outlook for patients is being transformed by the expanding treatment armamentarium. After having sorafenib as the only available systemic therapy for more than a decade, we now have 5 additional active agents with which to manage this disease. With these welcome advancements, however, come important questions about patient selection, sequencing of therapies, and management of unfamiliar toxicities.

Please join us at Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular Carcinoma, a satellite symposium being held in San Francisco in January 2019. This program is designed to help you assess the latest available safety and efficacy data related to the care of patients with HCC.

At this engaging, interactive, case-based symposium, a panel of renowned experts in HCC will not only arm you with a knowledge of the latest clinical trial data, but they will also provide nuanced insights into the most pressing clinical issues you face in the management of patients with HCC in your own practice. You will have the opportunity to question how the faculty leverage existing clinical evidence to make decisions about selecting the best therapies for their patients, sequencing these novel agents, and managing toxicities to optimize patient outcomes.

By participating in this exciting program, you will learn about:

  • The rationale for the development of emerging novel agents in HCC
  • Key clinical trial data that is rapidly altering how we treat patients with HCC
  • Evidence-based strategies for sequencing therapies across the course of disease for your patients with HCC
  • Ways to recognize and mitigate toxicities associated with immunotherapies and other novel approaches that might be less familiar to you

Target Audience

This educational program is directed toward all attendees of the Gastrointestinal Cancers Symposium, including medical oncologists, surgical oncologists, radiation oncologists, hepatologists, and gastroenterologists interested in the treatment of HCC.

Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with HCC are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanistic rationales underlying recent targeted drug development in HCC and how they relate to HCC biology
  • Summarize efficacy and safety outcomes from pivotal clinical trials of patients with advanced HCC
  • Evaluate recent clinical trial evidence and patient characteristics to inform optimized sequencing decisions in the management of patients with HCC
  • Outline strategies to mitigate the treatment-related toxicities of current and emerging therapies for the management of HCC

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai, Inc. and Exelixis, Inc.

Activity Chair

Alan P. Venook, MD, FASCO
The Madden Family Distinguished Professor of
Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By